Key Takeaways
- Akeso’s bispecific antibody cadonilimab shows promising results in a Phase III trial for locally advanced cervical cancer.
- 100% of evaluated patients responded to treatment, with nearly 85% achieving a complete response.
- The trial highlighted a 75% 12-month progression-free survival rate among challenging patient demographics.
Significant Trial Outcomes
Chinese biotech company Akeso (HKEX: 9926) has unveiled promising early results from a Phase III trial involving its bispecific antibody, cadonilimab (AK104), combined with chemoradiotherapy for patients diagnosed with locally advanced cervical cancer. These results were discussed at the 2025 annual meeting of the Society of Gynecologic Oncology and stem from the safety run-in phase of the COMPASSION-18 study.
Cadonilimab targets both the PD-1 and CTLA-4 immune checkpoint pathways and has already secured approval in China for treating recurrent or metastatic cervical cancer following platinum-based chemotherapy. Notably, the safety run-in phase yielded an impressive response rate; 100% of evaluable patients showed positive reactions to the treatment, with nearly 85% attaining a complete response.
In terms of survival rates, the study reported a 12-month progression-free survival rate of 75%. The trial participants were notably difficult to treat, as the cohort included a higher percentage of patients exhibiting low PD-L1 expression and lower performance status, which adds to the significance of the findings.
These encouraging results reinforce the potential of cadonilimab as a vital therapeutic option for patients battling locally advanced cervical cancer, potentially altering treatment paradigms in this challenging patient population.
The content above is a summary. For more details, see the source article.